Prostate Cell News Volume 6.35 | Sep 18 2015

KDM4/JMJD2 Histone Demethylase Inhibitors Block Prostate Tumor Growth by Suppressing the Expression of AR and BMYB-Regulated Genes
Compound B3 is highly selective for a variety of cancer cell lines including PC3 cells that lack androgen receptors (AR). B3 inhibited the in vivo growth of tumors derived from PC3 cells and ex vivo human prostate cancer explants. [Chem Biol] Abstract | Graphical Abstract

Differential IKK/NF-kappaB Activity Is Mediated by TSC2 through mTORC1 in PTEN-Null Prostate Cancer and Tuberous Sclerosis Complex Tumor Cells
The mechanistic role of the tumor suppressor tuberous sclerosis complex (TSC) was investigated in the regulation of IKK/NF-kappaB activity in PTEN-null prostate cancer and in TSC2 mutated tumor cells. [Mol Cancer Res] Abstract | Full Article

Splicing Factor Prp8 Interacts with NES^AR and Regulates Androgen Receptor in Prostate Cancer Cells
The authors showed that Prp8 could regulate novel nuclear export signal (NES^AR) function using shRNA knockdown of Prp8 coupled with a rapamycin export assay in mammalian cells and knockdown of Prp8 could induce nuclear accumulation of green fluorescence protein-tagged androgen receptor in PC3 cells. [Mol Endocrinol] Abstract | Full Article

LG308, a Novel Synthetic Compound with Anti-Microtubule Activity in Prostate Cancer Cells, Exerts Effective Antitumor Activity
Investigators found a novel synthetic compound 8-fluoro-N-phenylacetyl-1, 3, 4, 9-tetrahydro-β-carboline (LG308), which disrupted the microtubule organization via inhibiting the polymerization of microtubule in PC-3M and LNCaP prostate cancer cell lines. [J Pharmacol Exp Ther] Abstract | Full Article

Androgen Receptor-Mediated Growth Suppression of HPr-1AR and PC3-Lenti-AR Prostate Epithelial Cells
Investigators identified androgen-responsive genes that restrain cell cycle progression and proliferation of human prostate epithelial cell lines (HPr-1AR and PC3-Lenti-AR), and they investigated the mechanisms through which androgen receptor regulates their expression. [PLoS One] Full Article

Raloxifene Nanomicelles Reduce the Growth of Castrate-Resistant Prostate Cancer
Scientists encapsulated a selective estrogen receptor modulator, raloxifene, into poly(styrene-co-maleic acid), which demonstrated superior in vitro cytotoxicity compared with free drug against several castrate-resistant prostate cancer cell lines. [J Drug Target] Abstract

Cysteine-Rich Secretory Protein 3 Plays a Role in Prostate Cancer Cell Invasion and Affects Expression of PSA and ANXA1
Higher expression of cysteine-rich secretory protein 3 (CRISP-3) has been linked to poor prognosis and hence it has been thought to act as a prognostic marker for prostate cancer. It is proposed to have a role in innate immunity but its role in prostate cancer is still unknown. In order to understand its function, its expression was stably knocked down in LNCaP cells. [Mol Cell Biochem] Abstract

Inhibition of Gli/Hedgehog Signaling in Prostate Cancer Cells by “Cancer Bush” Sutherlandia frutescens Extract
The authors hypothesized the anti-cancer effect of S. frutescens was linked to its inhibition of the Gli/Hh signaling in prostate cancer. They found a dose- and time-dependent growth inhibition in human prostate cancer cells, PC3 and LNCaP, and mouse prostate cancer cell, TRAMP-C2, treated with S. frutescens methanol extract. [Cell Biol Int] Abstract

CLINICAL RESEARCH

Phase II Trial of Carboplatin, Everolimus and Prednisone in Metastatic Castrate Resistant Prostate Cancer Pretreated with Docetaxel Chemotherapy: A Prostate Cancer Clinical Trial Consortium Study
Investigators conducted a Phase II trial of the combination of carboplatin, prednisone and everolimus in metastatic castrate resistant prostate cancer as mTOR inhibition can overcome resistance to chemotherapy in prostate cancer. [Urology] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

Cancer Research UK and MedImmune Launch Ground-Breaking Biotherapeutics Research Center in Cambridge
A new laboratory that will focus on the discovery and development of novel biologic cancer treatments and diagnostics has been opened this week in Cambridge. The state-of-the-art CRUK-MEDI Alliance Laboratory is an innovative collaboration between Cancer Research UK, its commercial arm Cancer Research Technology, and MedImmune, the global biologics research and development arm of AstraZeneca. [Cancer Research UK] Press Release

WntResearch: Announces Phase I Study with Foxy-5 Is Completed
WntResearch announced that the last patient in their on-going clinical Phase I study with Foxy-5, has completed treatment at the last dose level according to the protocol. [WntResearch AB] Press Release

From our sponsor:
Interested in assays for human mammary stem and progenitor cells? Request your free wallchart.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the prostate cell community.

NEW Postdoctoral Fellow – Prostate Cancer Research (Rutgers Cancer Institute of New Jersey)

Postdoctoral Researcher – Epigenetic Modifiers (Van Andel Research Institute)

Postdoctoral Positions – Stem Cell, Development and Cancer Biology (Columbia University Medical Center)

Researcher – Role of Inflammatory Factors in the Pathogenesis of Prostate Cancer (Università degli Studi di Roma)

Staff Scientist – Cancer Modeling (Fred Hutchinson Cancer Research Center)

Postdoctoral Position – Drug Discovery and Action (University of Illinois)

Bioinformatician (GenomeDx Biosciences)

Harry Eagle Scholar Awards for Postdoctoral Candidates (Albert Einstein College of Medicine of Yeshiva University)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.